Effect of inflammatory response on joint function after hip fracture in elderly patients: A clinical study

Table 1 Patient characteristics of included patients, n (%)/mean ± SD

	Fair hip function after surgery (n = 67)	Excellent hip function after surgery (n = 52)	Total (n = 119)	t/χ2	P value
Age (yr)	76.88 ± 12.54	75.79 ± 12.05	76.4 ± 12.29	0.538	0.660
Sex				0.005	0.946
Female	46 (68.7)	36 (69.2)	82 (68.9)
Male	21 (31.3)	16 (30.8)	37 (31.1)
Hypertension				0.149	0.699
Yes	41 (61.2)	30 (57.7)	71 (59.7)
No	26 (38.8)	22 (42.3)	48 (40.3)
Diabetes				0.008	0.929
Yes	15 (22.4)	12 (23.1)	27 (22.7)
No	52 (77.6)	40 (76.9)	92 (77.3)
Types				0.030	0.862
Femoral neck	32 (47.8)	24 (46.2)	56 (47.1)
Trochanteric	35 (52.2)	28 (53.8)	63 (52.9)
Surgical method				0.016	0.899
PFNA	34 (50.7)	27 (51.9)	61 (51.3)
THA	33 (49.3)	25 (48.1)	58 (48.7)
Time from injury to
Surgery	4.69 ± 2.85	5.15 ± 2.82	4.89 ± 2.84	0.876	0.425
Neut	6.09 ± 2.38	6.49 ± 2.36	6.29 ± 2.36	0.643	0.806
Lymph	1.20 ± 0.61	1.14 ± 0.44	1.17 ± 0.53	0.455	0.152
IL-6	53.08 ± 28.24	24.58 ± 9.57	37.03 ± 24.43	2.54	0.012
IL-8	47.99 ± 23.39	24.06 ± 10.48	34.52 ± 20.98	7.47	< 0.01
IL-10	11.43 ± 4.83	9.44 ± 3.89	10.31 ± 4.42	2.49	0.014
CRP	21.76 ± 18.12	10.00 ± 5.55	15.14 ± 13.91	5.022	< 0.01
C1q	207.44 ± 49.24	174.84 ± 66.86	189.08 ± 61.75	2.949	0.004

PFNA: Proximal femoral nail antirotation; THA: Total hip arthroplasty; IL: Interleukin; CRP: C-reactive protein; C1q: Complement C1q.